Accounting for only 0.1–0.2 % of total malignancies and grow out of the retroperitoneal organs, retroperitoneal neoplasms are an uncommon yet significant group of neoplasms. Most essential retroperitoneal neoplasms emerge from mesodermal framework with liposarcoma, leiomyosarcoma and malignant fibrous histiocytoma together, representing above 80 % of essential retroperitoneal sarcomas, which is a difficult to treat condition for its localized aggression and clinical particularity. Remaining retroperitoneal masses emerge prevalently from nervous system. Difficulties encountered by surgeons during resection of a retroperitoneal sarcoma of exceptional size, attributable to anatomical site, to nonappearance of an anatomically apparent vascular-lymphatic peduncle and to adhesions contracted with adjoining organs and with large vessels. At present for retroperitoneal soft tissue sarcomas, there’s no productive chemotherapy present, and because of radiotoxicity influencing contiguous intra-abdominal organs, radiotherapy has restricted effectiveness yet without precedence in overall survival.